Kevin Drum

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Today, LA Times columnist David Lazarus answers a question I’ve been curious about for some time: where do the generic names for drugs come from? For example, the two chemo drugs I take are Pomalyst™ and Darzalex™, aka pomalidomide and daratumumab. But where do those generic names come from?

The answer, it turns out, is two women who work for USAN, the United States Adopted Names program. Stephanie Shubat explains how they come up with generic names for pharmaceuticals:

Shubat said this is done primarily by assigning uniform “stems” to drug names — that is, drugs with similar structures or purposes will have similar-sounding names, or parts of their names. The anti-anxiety drug lorazepam, for instance, would share “azepam” with similar medications; cortisone derivatives would have “cort” somewhere in their generic name.

The artistry comes in the assignation of a prefix, Shubat said. Unlike with celecoxib, the prefix shouldn’t hark back to the name-brand drug. Nor should it be potentially offensive in any language….She also said USAN will put the kibosh on generic names that include the letters W, K, H, J and Y, because they could create confusion abroad for non-English speakers with different pronunciations….“Sometimes I look at license plates for new prefix ideas,” Shubat confided. “Sometimes I borrow from the names of cats or dogs.”

I figured out the “stem” part of this long ago, since similar drugs usually have identical stems. But I could never make any sense out of the stuff before that. I always figured it must have something to do with the specific chemical compound, but boy was I wrong. It comes from license plates and cat names. Yeesh.

However, I’m curious about Shubat’s claim that they no longer allow generic names that are too similar to the trademarked name. Take a look at the two chemo drugs I use. Both of them borrow the first three letters of the trademark name as the first three letters of the generic name. Apparently the pharmaceutical folks are trickier about getting their way than Shubat thinks.

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

WE CAME UP SHORT.

We just wrapped up a shorter-than-normal, urgent-as-ever fundraising drive and we came up about $45,000 short of our $300,000 goal.

That means we're going to have upwards of $350,000, maybe more, to raise in online donations between now and June 30, when our fiscal year ends and we have to get to break-even. And even though there's zero cushion to miss the mark, we won't be all that in your face about our fundraising again until June.

So we urgently need this specific ask, what you're reading right now, to start bringing in more donations than it ever has. The reality, for these next few months and next few years, is that we have to start finding ways to grow our online supporter base in a big way—and we're optimistic we can keep making real headway by being real with you about this.

Because the bottom line: Corporations and powerful people with deep pockets will never sustain the type of journalism Mother Jones exists to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate